You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR IMEGLIMIN


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Imeglimin

Trial ID Title Status Sponsor Phase Summary
NCT01951235 ↗ A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes Completed Poxel SA Phase 2 This study will assess the efficacy and safety/tolerability of 4 doses of Imeglimin versus placebo. The study will be performed in subjects with type 2 diabetes either naive of treatment or previously treated with an oral monotherapy excluding thiazolidinedione.
NCT02373150 ↗ Safety, Tolerability and PK of Imeglimin in Japanese Volunteers Completed Poxel SA Phase 1 This study will assess the pharmacokinetics of single and repeated doses of imeglimin in healthy Japanese subjects, and the safety and tolerability of single and repeated doses of imeglimin in healthy Japanese subjects.
NCT02924337 ↗ Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects Completed Poxel SA Phase 1 The purpose of this study is to assess the effect of a single therapeutic dose and a single supra-therapeutic dose of imeglimin on the QT/QTc interval
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Imeglimin

Condition Name

Condition Name for
Intervention Trials
Type 2 Diabetes Mellitus 2
Healthy 1
Hepatic Impairment 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for
Intervention Trials
Diabetes Mellitus, Type 2 3
Diabetes Mellitus 3
Liver Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Imeglimin

Trials by Country

Trials by Country for
Location Trials
United Kingdom 4
Japan 1
Germany 1
Latvia 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Imeglimin

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 6
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Imeglimin

Sponsor Name

Sponsor Name for
Sponsor Trials
Poxel SA 6
Sumitomo Pharma Co., Ltd. 1
National Center for Global Health and Medicine, Japan 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 7
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.